Capital Advantage Portfolio holdings
Top Buys
Top Sells
| 1 |
Vanguard Intermediate-Term Corporate Bond ETF
VCIT
|
+$954K |
| 2 |
Lumentum
LITE
|
+$544K |
| 3 |
Advanced Micro Devices
AMD
|
+$283K |
| 4 |
Apple
AAPL
|
+$274K |
| 5 |
Pfizer
PFE
|
+$234K |
Sector Composition
| 1 | Technology | 7.03% |
| 2 | Industrials | 1.15% |
| 3 | Financials | 1.13% |
| 4 | Energy | 0.84% |
| 5 | Consumer Discretionary | 0.76% |
Similar funds
Capital Advantage's Q4 2025 Portfolio in Review
As of Q4 2025, Capital Advantage held 150 positions worth $741M, up 11% from $665M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Capital Advantage deployed $59.4M of net new capital in Q4 2025, opening 12 new positions and adding to 86 existing holdings. Its largest new stake was SoFi Technologies: 31,931 shares worth $836K.
By sector, the portfolio is most concentrated in Technology at 7% of assets, down from 7.5% a quarter earlier, followed by Industrials and Financials.
On the sell side, the largest reduction was Vanguard Intermediate-Term Corporate Bond ETF, an estimated $954K trimmed.
- Capital Advantage's largest Q4 2025 buy was SoFi Technologies: 31,931 shares worth $836K.
- Capital Advantage added most to iShares Ultra Short Duration Bond Active ETF in Q4 2025, an estimated $32M increase.
- Capital Advantage's biggest Q4 2025 reduction was Vanguard Intermediate-Term Corporate Bond ETF, cutting an estimated $954K.
- Capital Advantage fully exited Pfizer in Q4 2025, selling an estimated $234K.
- Capital Advantage's ten largest holdings make up 56% of its $741M portfolio in Q4 2025.
- Capital Advantage opened 12 new positions and closed 1 in Q4 2025.
- Capital Advantage's portfolio value rose 11% quarter-over-quarter to $741M.
Based on Capital Advantage's 13F filing for Q4 2025, filed 7 Jan 2026.